Inhibitors of the anaplastic lymphoma kinase

@article{Mologni2012InhibitorsOT,
  title={Inhibitors of the anaplastic lymphoma kinase},
  author={Luca Mologni},
  journal={Expert Opinion on Investigational Drugs},
  year={2012},
  volume={21},
  pages={985 - 994}
}
  • L. Mologni
  • Published 14 June 2012
  • Biology, Chemistry
  • Expert Opinion on Investigational Drugs
Introduction: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase normally expressed in the developing nervous tissue. Genetic alterations of ALK are associated with a number of cancers, including anaplastic large cell lymphoma (ALCL) and a subset of non-small cell lung cancer (NSCLC). Standard therapies for these diseases include surgery plus unspecific cytotoxic agents, with a low therapeutic window and significant treatment-associated systemic toxicity. A few small-molecule… 
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review
TLDR
The focus of ALK research appears to have shifted toward inhibitors that display activity against resistant mutants unearthed in clinical studies with crizotinib, and six additional ALK inhibitors have entered clinical trials.
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
TLDR
This review addresses some therapeutic considerations with regard to the use of ALK inhibitors in ALK-positive lymphomas where, in spite of the advanced stage of the disease, long-lasting responses could be obtained in a substantial portion of heavily pretreated patients.
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.
  • L. Mologni
  • Biology, Medicine
    World journal of clinical oncology
  • 2015
TLDR
It is opinion of the author that drug-resistance is likely to arise under any treatment, due to intrinsic heterogeneity and adaptability of cancer, and drugs that are rapidly effective in order not to allow enough time for tumor evolution are needed.
Expanding the portfolio of anti-ALK weapons.
  • L. Mologni
  • Biology, Chemistry
    Translational lung cancer research
  • 2015
TLDR
Ceritinib is a novel selective ALK inhibitor with preclinical activity against crizotinib-resistant ALK mutants, and was approved by FDA in April 2014 on the basis of clinical evaluation.
Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
TLDR
The authors discuss the role of ALK-Rs in the prediction of clinical–pathological features of NSCLCs and the technical problems related to their determination in specimens, and summarize the strategies that in the future could overcome these mechanisms of escape.
ALK inhibitors for clinical use in cancer therapy.
TLDR
This review addresses some clinical considerations on the use of ALK inhibitors in ALK positive tumors and on the development of resistance to them.
Anaplastic Lymphoma Kinase in Cutaneous Malignancies
TLDR
The characterization ofALK-positivity in these cutaneous malignancies presents exciting opportunities for utilizing ALK-targeted inhibitors in the treatment of these diseases.
Using the Second-Generation ALK Inhibitor AP 26113 in Human NPM-ALK – Positive Anaplastic Large Cell Lymphoma
TLDR
This work defines reliable ALCL model systems of AP26113 resistance and provides a valuable tool in the management of all cases of relapse upon NPM-ALK–targeted therapy, and provides the potential for second-line therapies to overcome Crizotinib resistance.
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma
TLDR
This work defines reliable ALCL model systems of AP26113 resistance and provides a valuable tool in the management of all cases of relapse upon NPM-ALK–targeted therapy, and provides the potential for second-line therapies to overcome Crizotinib resistance.
Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models
TLDR
Induction of ALK by EGFR inhibitor is identified as a novel mechanism potentially relevant to resistance to EGfr inhibitor, a high ratio of response of HNSCC patient-derived tumor cells to a combination of ALk and EGFR inhibitors, and applicability of repurposing ALK inhibitors to HNS CC that lack ALK aberrations.
...
...

References

SHOWING 1-10 OF 94 REFERENCES
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
TLDR
The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.
ALK fusion genes in children with atypical myeloproliferative leukemia
TLDR
It is shown that ALK is rarely but recurrently rearranged in children with myeloid diseases, indicating the great clinical potential that anti-ALK therapies may acquire in the near future.
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
TLDR
Findings from a series of lung cancer patients with acquired resistance to the ALK TKI crizotinib reinforce the need to tailor therapeutic strategies to the specific underlying drug resistance mechanisms in the tumors to improve clinical outcomes.
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
TLDR
The discovery of ALK gene mutations in thyroid cancer that may rationalize clinical evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting are reported and suggest efforts to clinically evaluate the use ofALK kinase inhibitors to treat patients who harbor ATCs with these mutations.
Biological role of anaplastic lymphoma kinase in neuroblastoma.
The anaplastic lymphoma kinase in the pathogenesis of cancer
TLDR
This Review will analyse how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacological tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous system, accounts for approximately 15% of all deaths due to childhood cancer. High-risk neuroblastomas are rapidly
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
TLDR
The discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor are reported.
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
TLDR
A model of acquired resistance to ALK inhibitors is developed and it is shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.
...
...